Yung-Hsing Huang

Years Active: 2018-2021
Publications (10 Years): 4

Houston Methodist Research Institute

University of Alberta (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Houston Methodist Research Institute Apr 01 2019

United States

Postdoctoral Fellow :: Center for Translational Research in Hematologic Malignancies

Education History

University of Alberta Sep 01 2014 - Nov 19 2018

Canada

PHD :: Laboratory Medicine and Pathology

University of British Columbia Sep 01 2011 - Aug 30 2013

Canada

BSC :: Biochemistry and Molecular Biology

Publications

Qiang Wang, Zhijuan Lin, Zhuo Wang, Lingqun Ye, Miao Xian, Liuling Xiao, Pan Su, Enguang Bi, Yung-Hsing Huang, Jianfei Qian, Lintao Liu, Xingzhe Ma, Maojie Yang, Wei Xiong, Youli Zu, Sai Ravi Pingali, Bing Xu, Qing Yi
RARγ activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway. Blood (2021)
Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma. Cancers 11 (2) (2019)
Moinul Haque, Jing Li, Yung-Hsing Huang, Meaad Almowaled, Carter J Barger, Adam R Karpf, Peng Wang, Will Chen, Suzanne D Turner, Raymond Lai
NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma. Cancers 11 (8) (2019)
Yung-Hsing Huang, Ommoleila Molavi, Abdulraheem Alshareef, Moinul Haque, Qian Wang, Michael P Chu, Christopher P Venner, Irwindeep Sandhu, Anthea C Peters, Afsaneh Lavasanifar, Raymond Lai
Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. Cancers 10 (6) (2018)

Yung-Hsing Huang.css-eqlu8i{font-size:small;padding-left:4px;}